Showing 4881-4890 of 5910 results for "".
- GenSight Biologics Announces Publication of Results from Lumevoq REVERSE Pivotal Phase 3 Trialhttps://modernod.com/news/gensight-biologics-announces-publication-of-results-from-lumevoq-reverse-pivotal-phase-3-trial/2478644/GenSight Biologics announced that the journal Science Translational Medicine has published results from the REVERSE pivotal phase 3 clinical trial of Lumevoq gene therapy in ND4 Leber Hereditary Optic Neuropathy (LHON) subjects along with key results from a non-human primate stu
- No Red Flags in FDA Review of Pfizer, BioNTech’s COVID-19 Vaccine Candidatehttps://modernod.com/news/no-red-flags-in-fda-review-of-pfizer-biontechs-covid-19-vaccine-candidate/2478641/In briefing documents released Tuesday ahead of an FDA advisory committee meeting on December 10, agency staff said that efficacy data submitted by Pfizer and BioNTech in support of BNT162b2 are “consistent” with recommendations previously detailed in guidance on the emergency-use aut
- Norlase Announces Newly Appointed Distributors into Major European Marketshttps://modernod.com/news/norlase-announces-newly-appointed-distributors-into-major-european-markets/2478640/Norlase has announced new distributor partnerships developed to advance market growth and global expansion of the Norlase family of green laser systems into France, Germany, Italy, Spain, and the United Kingdom. “We’re thrilled to announce that most ophthalmologists in Europe will no
- Aldeyra Announces First Patient Enrolled in the Phase 3 TRANQUILITY Trial of Reproxalap for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aldeyra-announces-first-patient-enrolled-in-the-phase-3-tranquility-trial-of-reproxalap-for-the-treatment-of-dry-eye-disease/2478638/Aldeyra Therapeutics announced enrollment of the first patient in the phase 3 TRANQUILITY trial of 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease. The multicenter randomized, double-masked, parallel design, vehicle-controlled clinical trial will assess the effica
- Novaliq Announces First Patient Randomized in the ESSENCE-2 Phase 3 Trial of Dry Eye Treatment CyclASolhttps://modernod.com/news/novaliq-announces-first-patient-randomized-in-the-phase-3-trial-essence-2-of-dry-eye-treatment-cyclasol/2478637/Novaliq announced that it has initiated the randomization of patients in its phase 3 clinical trial ESSENCE-2 that is designed to replicate efficacy results of the previous phase 2/3 ESSENCE-1 trial. “The initiation of this second registrational trial represents a key milestone for b
- Tilak Healthcare Partners With Novartis to Promote Mobile App OdySighthttps://modernod.com/news/tilak-healthcare-partners-with-novartis-in-ophthalmology/2478634/Tilak Healthcare, a provider of digital therapeutics, has announced an agreement with Novartis Pharma for the promotion internationally of OdySight, Tilak Healthcare’s first clinically validated mobile app for patient remote vision monitoring. Financial terms of the deal were not disclosed
- RetinAI Announces Collaboration with Novartis to Provide Artificial Intelligence Solutions in Ophthalmologyhttps://modernod.com/news/retinai-announces-collaboration-with-novartis-to-provide-artificial-intelligence-solutions-in-ophthalmology/2478636/RetinAI Medical announced a multi-year collaboration with Novartis Pharma under which RetinAI’s IT solutions and artificial intelligence tools will be used to support multiple projects in ophthalmology and digital health. Financial terms of the deal were not disclosed. The first pro
- Supply Chain Snags Blamed For Cut to Pfizer COVID-19 Vaccine Rollout This Year: Reporthttps://modernod.com/news/supply-chain-snags-blamed-for-cut-to-pfizer-covid-19-vaccine-rollout-this-year-report/2478626/Pfizer and BioNTech expect to ship only half of the 100 million doses of COVID-19 vaccine they had originally targeted for worldwide delivery this year because of hurdles encountered with the supply chain, according to a report in The Wall Street Journal on Thursday. A person directly in
- CMS Issues Final 2021 ASC Payment Rule: 2.4% Increase for Facilitieshttps://modernod.com/news/cms-issues-final-2021-asc-payment-rule-2-4-increase-for-facilities/2478624/On December 2, the Centers for Medicare and Medicaid Services (CMS) issued its final CY 2021 payment rate regulation for hospital outpatient departments (HOPD) and ambulatory surgery centers (ASC). ASC Payme
- Focus Vision Supplements Now Offer Eyelid Products to Soothe Dry Eye and Aid in Postoperative Healinghttps://modernod.com/news/focus-vision-supplements-now-offer-eyelid-products-to-soothe-dry-eye-and-aid-in-postoperative-healing/2478622/Covalent Medical, owner of Focus Vision Supplements, has developed two new products to aid in pre/postoperative care and soothe the symptoms of occasional dry eye and blepharitis. Focus Eyelid Scrub Formula is a preservative-free, deep-cleaning foam eyelid cleanser